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Abstract
Multiple myeloma (MM) remains an incurable disease
despite recent therapeutic improvements. The ability to
detect and characterize MM circulating tumour cells
(CTCs) in peripheral blood provides an alternative to
replace or augment invasive bone marrow (BM) biopsies
with a simple blood draw, providing real-time, clinically
relevant information leading to improved disease manage‐
ment and therapy selection. Here we have developed and
qualified an enrichment-free, cell-based immunofluores‐
cence MM CTC assay that utilizes an automated digital
pathology algorithm to distinguish MM CTCs from white
blood cells (WBCs) on the basis of CD138 and CD45
expression levels, as well as a number of morphological
parameters. These MM CTCs were further characterized
for expression of phospho-ribosomal protein S6 (pS6) as a
readout for PI3K/AKT pathway activation. Clinical feasi‐
bility of the assay was established by testing blood samples
from a small cohort of patients, where we detected popu‐
lations of both CD138pos and CD138neg MM CTCs. In this
study, we developed an immunofluorescent cell-based
assay to detect and characterize CTCs in MM.
Keywords Circulating Tumour Cells, Rare Cells, Liquid
Biopsy, Multiple Myeloma, Biomarkers, Peripheral Blood,
Drug Development
1. Introduction
Multiple myeloma (MM) is a neoplasm of plasma cells and
is the second most common blood malignancy worldwide
[1], accounting for 1% of all cancers, 13% of hematologic
malignancies [2], and causing approximately 20% of
hematologic malignancy-related deaths [3]. Though MM is
still incurable, in the last decade patients with MM have
experienced an increased overall survival (up to eight
years) due to considerable improvements in disease
management, disease monitoring, and the introduction of
several new therapeutics, including bortezomib, lenalido‐
mide and thalidomide [1, 2, 4-9].
A number of signalling pathways are known to be dysre‐
gulated in MM, which contributes to disease progression.
In particular, aberrant activation of growth factor pathways
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results in downstream activation of the PI3K/AKT signal‐
ling cascade, promoting cell proliferation, survival and
tumour growth [10, 11]. Targeting the PI3K/AKT pathway
in MM has been shown to induce cell-cycle arrest and
apoptosis in MM cell lines and patient myeloma cells
[12-14]. Multiple clinical trials involving the use of
PI3K/AKT pathway inhibitors to treat relapsed or refracto‐
ry MM are underway ([10, 15], clinicaltrials.org).
Further improvements in MM treatment will require
development of novel targeted therapies in combination
with diagnostic tests, as well as sensitive technologies to
monitor residual disease in patients during remission.
Since cancer is a heterogeneous and dynamic disease as
demonstrated by inter-patient variability [16, 17] and intra-
patient evolution over time [17-22], the management of
patients on targeted therapies requires detailed and up-to-
date molecular roadmaps, for which repeated and non-
invasive sampling will be crucial [23, 24]. Current standard
of care requires invasive and painful bone marrow (BM)
biopsies, which are not ideal for routine observation of
patients’ progress in real time. Thus, the development of a
liquid (blood) biopsy for detection and molecular charac‐
terization of MM tumour cells in peripheral blood could
have broad clinical utility and improve patients’ quality of
life.
While originating in the BM, MM tumour cells are able to
migrate into the peripheral blood stream, from where they
can be isolated and characterized ([25] and references
therein). These MM circulating tumour cells (CTCs) have
been used as biomarkers to indicate active disease [26], to
assess disease stage [27], to stratify MM patients for
autologous stem-cells transplantation [28, 29], to predict
survival [30] and to monitor response to therapy [31]. While
flow cytometry is the most commonly used method to
analyse MM CTCs, the sensitivity of this technology
remains relatively low. Different groups using flow
cytometry report varying numbers of patients with
detectable CTCs ranging from 30-75% [27, 29, 32-34]. In
addition, for patients with MM CTCs, the numbers of MM
CTCs identified in peripheral blood were generally low [27,
33]. As an alternative to flow cytometry methods, Cell‐
search® technology, which utilizes magnetic particles
coated with anti-CD138 (syndecan-1) antibodies to enrich
MM CTCs from the blood, has been explored for its ability
to detect MM CTCs. Using this technology, MM CTCs were
isolated from 68% of MM patients [35-37]. However, this
enrichment-based approach would miss MM CTCs that are
CD138neg, which have been shown to possess stem cell-like
qualities and a higher clonogenic potential than their
CD138pos counterparts [38-41].
To overcome the limitations of BM biopsies and enrich‐
ment-based CTC detection methods, we aimed to develop
an assay that can detect all MM CTC subtypes, is flexible
for downstream molecular characterization and, at the
same time, can provide high-content morphological
information. Here we describe an enrichment-free MM
specific CTC assay based on the Epic Platform, which has
recently been analytically validated for CTCs of epithelial
origin [42]. This platform has demonstrated increased
sensitivity over the CellSearch® method [43-45], and has
been tested in a variety of solid tumour indications includ‐
ing non-small cell lung, prostate, bladder, pancreatic,
ovarian and breast cancers [45-47].
The MM CTCs assay used a combination of CD138 and
CD45 antibodies as well as a DAPI nuclear stain and
morphology. Although CD138 has been shown to be highly
expressed on most MM CTCs and is required for myeloma
cell adhesion [48, 49], a clinically significant population of
MM CTCs that express little to no CD138 has been descri‐
bed [38-41]. To increase sensitivity and ensure identifica‐
tion of the greater population of MM CTCs, including
CD138neg CTCs, we combined CD138 expression with
morphology characteristics and a secondary biomarker.
Due to the importance of the PI3K/AKT pathway in MM,
we elected to multiplex the MM CTC assay with a phospho-
ribosomal protein S6 (pS6), a common downstream
readout in PI3K/AKT signalling pathway studies [50]. This
approach provides a platform for enumerating and
characterizing CTC in MM patients.
2. Methods
2.1 Sample receipt, processing, and CTC detection using the epic
platform
Blood samples were collected in 10 mL cell-free DNA
preservative blood tubes (Streck, Omaha, NE) and shipped
to Epic Sciences for processing. Sample processing and
slide preparation procedures were described previously
[42, 44] and also summarized in Figure 1. Briefly, red blood
cell (RBC) lysis was performed using an ammonium
chloride-based buffer. Following centrifugation, all
nucleated cells were plated on up to 12 glass slides at a
concentration of three million nucleated cells per slide.
Slides were then frozen at -80 °C until CTC analysis. On
testing, two slides were thawed and immunofluorescently
stained with an antibody cocktail targeting CD138 (BD
Pharmingen, CA), CD45, pS6; nuclei were visualized with
4’,6-Diamidino-2-phenylindole dihydrochloride (DAPI,
ThermoFisher). Slides were scanned using a high-speed
fluorescent imaging system. A proprietary digital pathol‐
ogy algorithm identified candidate CTCs that were then
reviewed by trained technicians to classify CTCs [42] into
one of the following categories:
• Traditional MM CTCs: CD138pos/CD45neg cells with
intact, DAPI stained nuclei and morphologically distinct
from surrounding white blood cells (WBCs)
• MM CTC clusters: two or more adjacent CTCs with
shared cytoplasmic boundaries, containing at least one
traditional MM CTC
• CD138neg MM CTCs: CD138neg/CD45neg cells with intact
DAPI nuclei and morphologically distinct from sur‐
rounding WBCs
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• Apoptotic CTCs: CD138pos/CD45neg cells with DAPI
pattern of chromosomal condensation/fragmentation
and/or membrane blebbing.
The number of CTCs detected was reported as either CTC/
slide or CTC/ml of blood. Data analysis and graphing were
performed using Excel (Microsoft) and Prism software
(GraphPad).
Figure 1
CD138, CD45, DAPI, open (pS6)
CD138
CD45
Figure 1. Epic Platform workflow for sample preparation, CTC enumeration
and biomarker analysis. On patient blood sample receipt at Epic Sciences,
(1) whole blood is lysed and nucleated cells (3 x 106 per slide) are deposited
on to each of 10-12 microscope slides and stored at -80 ºC until analysis. (2)
Two slides per patient sample are thawed and cells are immunofluorescent‐
ly labelled for CD138, CD45 and one additional biomarker, such as pS6.
Nuclei are stained with DAPI. (3) Slides are scanned by a high-speed
fluorescent imaging system. (4) CTC and CTC subtypes are detected and
biomarker expression is quantitated utilizing Epic’s proprietary digital
pathology software. All CTC and CTC subtypes are confirmed by a trained
human technician. (5) CTC enumeration and biomarker expression results
are compiled and reported. This figure is adapted from [42].
2.2 Assay development and qualification of MM CTC assay
For assay development and qualification, cell line cell
(CLC) control slides were prepared following standard
sample preparation procedures described above using
healthy donor (HD) samples spiked with appropriate
numbers of the immunoglobulin A lambda myeloma-
derived, MM.1S cells. MM.1S cells were purchased from
ATCC (Manassas, VA) and cultured in RPMI-1640 media
supplemented with 10% foetal bovine serum at 37 °C with
5% CO2.
Six concentrations of a mouse monoclonal antibody against
human CD138 (BD Pharmingen, CA) were tested to
determine the optimal antibody concentration ranging
from 0 μg/mL to 10 μg/mL. Fixation and permeabilization
conditions were also optimized to obtain best signal-to-
noise ratios. To determine the specificity of the anti-CD138
antibodies, control slides were stained with antibody
cocktails with either the anti-CD138 antibody omitted (no
primary control) or substituted with an appropriate isotype
control antibody (isotype control).
For assay qualification, serial dilutions of MM.1S cells were
spiked-in to HD WBCs at 1, 10, 100 and 1000 CLCs per three
million WBCs per slide. Three sets of three slides at each
CLC to WBC ratio listed above were prepared. The slides
were stained in triplicate to determine repeatability and on
three separate days to determine reproducibility. Assay
sensitivity, accuracy and linearity were determined by
plotting number of expected CLCs against number of
recovered CLCs. In addition, assay specificity was assessed
by staining one slide each of HD WBC-only samples from
five individual healthy donors.
2.3 Patient feasibility of CTC detection in MM patients
Blood samples from three Stage III MM patients (on active
treatment) were sourced from Conversant Bio (Huntsville,
AL), collected in EDTA (BD Vacutainer®) tubes and
shipped overnight to Epic Sciences for processing. Stand‐
ard sample processing procedures were followed except
blood was lysed using BD Phosflow™ Lyse/Fix Buffer 5X
(BD Biosciences, San Diego, CA), and two slides from each
patient were immunofluorescently labelled with an
antibody cocktail against CD138, CD45, pS6 and stained
with DAPI for MM CTC analysis. Following staining, CTCs
were identified using Epic’s proprietary algorithm as
described above, and expression levels of CD138 and pS6
were measured.
3. Results
3.1 CD138 MM CTC assay development
The anti-CD138 antibody was titrated on samples prepared
from spiking a MM cell line, MM.1S, into HD WBCs, and
the optimal antibody concentration providing the highest
signal levels for the MM CTC assay was determined to be
1 μg/mL (Figure 2A). Although MM.1S cells represented a
clonal population, a wide range of CD138 expression was
observed (Figure 2B), which likely reflects the expected
CD138 expression range in patient cell populations. To
assess the specificity of the assay, we used no primary
antibody control, where the anti-CD138 antibody was
omitted, and an isotype control, where the anti-CD138
antibody was substituted with an appropriate isotype
control antibody. As expected, neither of the controls
detected any CD138pos/CD45neg cells (Figures 2A, 2B, and
Figure 2C), indicating the anti-CD138 antibody was
specific. Representative images of an MM.1S cell with an
irregularly shaped nucleus and small cytoplasm stained
with the MM CTC assay (Figure 2D), showed strong and
specific membrane-localized CD138 signals and absence of
CD45 signals on the MM.1S cell, while the surrounding
WBCs were CD45pos/CD138neg.
3.2 CD138 MM CTC assay qualification: Specificity, sensitivity,
linearity, accuracy, repeatability and reproducibility
To qualify the MM CTC assay for patient sample analysis,
assay specificity, sensitivity, linearity, accuracy, reprodu‐
cibility and repeatability were evaluated. A schematic of
the assay qualification setup is shown in Figure 3A. To
further confirm the specificity of the MM CTC assay (in
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addition to the no primary and isotype controls described
above), the assay was tested on WBCs isolated from five
individual healthy donors and no CD138 positive cells
were detected (data not shown).
Run Expected Mean St dev % CV
1
1 1 0.6 43.3
10 9 1.5 17.6
100 62 9.1 14.7
1000 994 26.1 2.6
2
1 1 1.2 173.2
10 5 0.6 10.8
100 57 5.7 10.0
1000 948 46.2 4.9
3
1 0 0.6 173.2
10 7 3.5 49.5
100 59 8.7 14.9
1000 951 23.3 2.5
Table 1. The MM CTC assay is repeatable across titration points. Intra-assay
variability was calculated for each titration point from triplicates stained on
three separate days. High consistency within the assay (low intra-assay
variability, % CV<20) was demonstrated for most conditions. High % CV for
n = 1 and 10 was expected due to high variability for detecting low number
of cells.
Assay sensitivity was measured by the ability of the MM
CTC assay to detect down to a single MM.1S cell spiked-in
to three million HD WBCs on a single slide. The results
confirmed the assay is highly sensitive and validated its
cut-off value. On average, one MM.1S cell per slide was
detected in slides at the lowest titration point, with a range
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Figure 2. Anti-CD138 immunofluorescence-based assay was developed to
detect MM CTCs. Antibody titration was performed using a monoclonal
IgG1 anti-CD138 antibody on samples prepared from MM.1S cells spiked
into healthy donor blood. Bar graph (A) shows mean CD138 signal ± SEM
and scatter plot. (B) shows CD138 signal on each individual MM.1S cell
detected. The red bar and dots denote the optimal antibody concentration
chosen for the assay. The dotted line indicates the system’s cut-off value. (C)
Staining the same samples with the isotype control antibody or with 0
μg/ml primary antibody concentration (identified by -) resulted in no MM.
1S cells detected, confirming the specificity of the antibody staining. (D)
Representative images (40x magnification) of an MM.1S cell stained with the
MM CTC assay (DAPI, CD45, CD138). Note that MM.1S cells are CD138pos,
CD45neg and DAPIpos, whereas WBCs are CD138neg, CD45pos and DAPIpos.
more, the assay showed excellent linear correlation
(R2=0.9986) and an accuracy of 97.5% between number of
expected cells and number of recovered cells ranging from
1 to 1000 cells (Figure 3B). These results also suggest the
assay is unbiased since the CD138 expression profile for the
CLC population remained consistent regardless of the total
number of cells detected, and similar to that observed
previously (Figure 3C).
Repeatability (intra-assay variability) of the MM CTC assay
was determined by staining triplicate slides per titration
point, while reproducibility (inter-assay variability) of the
assay was determined by staining three sets of slides on
three separate days. The results showed that the assay is
highly repeatable and reproducible. At each titration
(except for the lowest titration points, as expected), the
intra-assay variability expressed as % CV between the
triplicate slides (Table 1), and the inter-assay variability
expressed as % CV between three runs (Table 2) were below
20%.
Expected Mean St dev % CV Range
1 1 0.8 107.2 0-2
10 7 2.4 34.3 3-10
100 59 7.3 12.3 49-72
1000 964 36.5 3.8 909-1019
Table 2. The MM CTC assay is reproducible across titration points. Inter-
assay variability was calculated from data for each titration point across the
three runs. High consistency between assay runs (low inter-assay variability,
% CV<20) was demonstrated for most data points. High % CV for n = 1 and
10 was expected due to high variability for detecting low number of cells.
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Figure 3. The Epic MM CTC assay is sensitive, specific, linear, accurate,
repeatable and reproducible. (A) Experimental scheme for assay character‐
ization is shown. Sample slides were prepared with a 10-fold titration series
of 1, 10, 100, and 1000 MM.1S cells spiked into three million (3M) HD WBCs
per slide. Triplicate slides from each titration point were stained with the
MM CTC assay on three separate days. (B) The MM CTC assay is sensitive
(limit of detection down to one cell), linear (R2=0.9986), with an accuracy of
97.5% (derived from the slope of the line). The graph shows mean ± SD
numbers of MM.1S cells detected plotted against the number of MM.1S cells
expected. (C) Heterogeneity of CD138 signals (mean ± SEM) were observed
in MM.1S cells, but profiles of CD138 signals remained consistent regardless
of number of MM.1S cells detected. The data were combined from the total
of nine replicates (triplicate slides, three runs).
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Taken together, these results demonstrated that the MM
CTC assay was specific, sensitive, linear, accurate, un‐
biased, repeatable and reproducible for detecting MM-
derived CLCs.
3.3 Patient feasibility studies using CD138 MM CTC assay
To determine the clinical feasibility of the MM CTC assay,
we tested blood samples from three Stage III MM patients
undergoing active treatment. Since previous work demon‐
strated the utility of pS6 in cytometry-based multiple
myeloma CTC assays [50] and because the addition of an
extra MM biomarker could potentially help identify a
subpopulation of CD138neg/CD45neg MM CTCs, we multi‐
plexed the MM CTC assay to include pS6 as a marker for
PI3K/AKT pathway activation.
The MM CTC assay identified CD138pos MM CTCs in all
three patient samples tested (Figures 4A, 4B, Table 3),
confirming the assay’s ability to detect MM CTCs in clinical
samples. Average CD138pos MM CTC counts of 63
CTCs/ml, 499 CTCs/ml and 450 CTCs/ml were identified in
samples from patients one, two and three, respectively.
Notably, each patient sample displayed a heterogeneous
population of CTCs with varying CD138 levels (Figure 4B).
In addition to traditional MM CTCs, CD138pos CTCs,
apoptotic CTCs (characterized by abnormal nuclear
morphologies, such as chromosomal condensation and/or
nuclear fragmentation) and CTC clusters (defined as two
or more touching CTCs) were also detected in these
samples (Table 3).
CTC category (all CD45neg) Patient 1 Patient 2 Patient 3
CD138pos CTCs
Traditional CTCs 157 1289 841
CTC clusters 0 1 2






























Table 3. CTC populations in patient samples. The table summarizes the total
number of CTCs from each category identified on two slides per patient. The
percentage of total CTC count is reported in parentheses.
By multiplexing the MM CTC assay with pS6 detection, we
were also able to identify MM CTCs with varying levels of
pS6 in all three patients’ samples (Figures 4A and 4D, Table
3). Interestingly, a subpopulation of CD138neg/pS6pos
‘putative’ CTCs were identified in samples from patients
two and three (Figure 4D). Patient three demonstrated the
largest subpopulation of CD138neg/pS6pos ‘putative’ CTCs
(59 CD138neg/pS6pos CTCs out of 286 pS6pos CTCs per mL of
blood). These CD138neg/pS6pos cells were classified as
‘putative’ MM CTCs based on CD45 negativity and distinct
morphology from surrounding WBCs (Figure 4E), includ‐
ing the presence of eccentric nuclei, which is a common
feature of MM cells [51].
4. Discussion
In this study, we developed a slide-based, enrichment-free
immunofluorescence assay using the Epic Platform to
detect, enumerate and characterize MM CTCs. This assay
utilized CD138 and CD45 expression levels as well as
morphological parameters to distinguish MM CTCs from
normal WBCs. Using a titration series of MM.1S cells
spiked into normal blood, we demonstrated the assay to be
linear and accurate. The assay can also be multiplexed with
one or two additional biomarkers to further characterize
MM CTCs (discussed below).
Patient feasibility of the MM CTC assay was established by
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Figure 4. Clinical feasibility of the Epic MM CTC assay was successfully
demonstrated using MM patient samples. Consistent numbers of CD138pos
cells (A) and pS6pos cells (B) were identified on each slide within each patient
sample tested (two slides were tested per patient sample and each black
diamond represents cell count on one slide; red number denotes the average
number of CD138pos or pS6pos CTCs/ml of blood). Patient CTCs also showed
heterogeneous CD138 (C) and pS6 (D) signal levels (combined data from
both slides per sample are shown; dotted lines indicate the negative cut-off
values for CD138 and pS6 signals). (E) Representative images (40 X
magnification) highlight the morphological characteristics of patient MM
CTCs consistent with their plasma cell origin, such as eccentric nuclei and
double-nucleated cells. Note the heterogeneity of patient MM CTCs: some
were CD138pos/pS6neg (E, top panel), some were CD138pos/pS6pos (E, middle
panel) and some were CD138neg/pS6pos (D and E, bottom panel).
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identified in all three patients ranging from 63 CTCs/mL to
498 CTCs/mL and pS6 expression levels were quantitated.
Patient MM CTCs exhibited a wide range of CD138
expression levels similar to that observed in MM.1S cells.
The intra- and inter-patient heterogeneity of MM CTCs was
also exemplified by varying cellular morphologies as well
as pS6 signal levels. Importantly, in addition to CD138pos/
CD45neg MM CTCs, a population of CD138neg/pS6pos/
CD45neg cells was also identified based on their pS6
expression and distinct MM-like cellular morphology.
CD138neg ‘putative’ MM CTCs are of particular interest as
they have previously been reported to possess increased
proliferative potential and correlate with poor prognosis
[38-41]. A further investigation is needed to analyse
characterization and confirmation of those 'putative’ CTCs.
Basic understanding of the significance of MM CTCs and
how they differ from clonal MM cells in the BM has been
hampered by the lack of a sensitive and unbiased method
to molecularly characterize these cells. Others have
endeavoured to profile MM CTCs by capturing, culturing
and comparing these cells to their resident BM counterparts
[25]. However, this type of approach could introduce
additional complexity due to ex vivo culturing of the MM
CTCs. The multiplexing and downstream cell-picking
capabilities of the Epic platform allow for biomarker
expression and genomic profiling using the MM CTC assay
described here with single-cell resolution in their native
environment, providing a unique opportunity to under‐
stand disease heterogeneity.
The ability to assess and characterize MM CTCs also opens
up new avenues for improving patient disease manage‐
ment. The invasiveness of BM biopsies limits their clinical
utility typically to time of diagnosis or at disease progres‐
sion. While they have been invaluable for diagnosis and for
stratifying patients into proper treatment groups and
clinical studies, they provide just a snapshot of a patient’s
disease state and are not feasible for continuous routine
observations. Blood tests, on the other hand, are minimally
invasive and are already performed at follow-up visits for
routine disease monitoring. Adding a blood-based MM
CTC assay to the current standard of care could present
physicians with a movie rather than a snapshot of patients’
disease evolution in real time, allowing for monitoring of
treatment response, emergence of treatment resistance,
appearance of potential new molecular targets and inform‐
ing treatment selection.
Due to the heterogeneous nature of patient CTCs, a method
capable of unbiased detection and analysis of all CTCs is
required to ensure accurate assessment of a patient’s
disease state. The MM CTC assay described here provides
an advantage over enrichment-based technologies, which
are inherently incapable of detecting the full array of CTCs
within each patient. Importantly, in addition to CD138pos/
CD45neg MM CTCs, in two of the three patients a clinically
important population of CD138neg/pS6pos/CD45neg cells was
also detected, based on their pS6 expression and distinct
MM-like cellular morphology. This approach may prove
useful clinically for pharmacodynamic testing in new
therapeutics development and for monitoring and charac‐
terizing an individual MM patient's disease via liquid
biopsies of the blood.
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